Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lacnotuzumab (MCS110) is a humanized monoclonal antibody targeting CSF-1, inhibiting the macrophage colony-stimulating factor pathway upstream components, used in retinal disease research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $447 | In Stock | |
5 mg | $1,400 | In Stock | |
10 mg | $2,240 | In Stock | |
25 mg | $4,210 | In Stock |
Description | Lacnotuzumab (MCS110) is a humanized monoclonal antibody targeting CSF-1, inhibiting the macrophage colony-stimulating factor pathway upstream components, used in retinal disease research. |
In vivo | Treatment of NOD/SCID mice with anti-human CSF-1 mAb Lacnotuzumab by subcutaneous injection of CHLA-255-Fluc NBs (given alone once weekly) reduced human monocyte-derived CD163 + cells but did not improve chemotherapy. [2] |
Alias | MCS110, MCS 110, Anti-Human B7-H3 |
Cas No. | 1831128-32-5 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.